Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | LMNA | P02545 | 6/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1899477 | 0.91 | KDM4E (0.53) | KDM4EALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL2174789 | 0.91 | KDM4E (0.53) | KDM4EALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL1899907 | 0.89 | KDM4E (0.56) | KDM4EALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL1897740 | 0.88 | CNR1 (0.56) | KDM4EALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL12409169 | 0.87 | KDM4E (0.54) | KDM4EALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL1898361 | 0.86 | RBP4 (0.45) | KDM4EALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL2173939 | 0.81 | KDM4E (0.61) | KDM4EALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL1900625 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL1901227 | 0.79 | KDM4E (0.65) | KDM4EALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL12409162 | 0.78 | MAPT (0.65) | KDM4EALDH1A1LMNASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973079-B2 | Methods and compounds for treating retinol-related diseases | REVISION THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | claimed |
| US-20090088435-A1 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | SIRION THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | US | claimed |
| US-20130012591-A1 | PROPHYLAXIS OF SKIN CANCER WITH RETINAMIDES | REVISION THERAPEUTICS, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-7973079-B2 | Methods and compounds for treating retinol-related diseases | REVISION THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973079-B2 | Methods and compounds for treating retinol-related diseases | REVISION THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973079-B2 | Methods and compounds for treating retinol-related diseases | REVISION THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| EP-2205234-A2 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | Sirion Therapeutics, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20090088435-A1 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | SIRION THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090088435-A1 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | SIRION THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090088435-A1 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | SIRION THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| WO-2009042444-A2 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | SIRION THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009042444-A2 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | SIRION THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012591-A1 | PROPHYLAXIS OF SKIN CANCER WITH RETINAMIDES | ALDH1A2, ALDH1A3, CRABP2 | KDM4E 462/4885ALDH1A1 60/4885LMNA 1930/4885 |
| US-20090088435-A1 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | RBP1, RBP4, ALDH1A2 | KDM4E 4096/4885ALDH1A1 40/4885LMNA 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.